Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical ...

T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...

When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

ENHERTU Followed by THP Before Surgery Resulted in Pathologic Complete Response in 67% of Patients w/High-Risk HER2 Positive ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...